Pharma BD Deal Intelligence
Merck & Co. Inc. / Acceleron Pharma Inc.
2021 · Acquisition/Merger · $11.5B · Complete
Announcement Sentiment
78
Strongly positive
Outcome Score
90
Worked — the deal delivered on its rationale.
Merck acquired Acceleron Pharma for approximately $11.5 billion ($180 per share in cash), gaining sotatercept, an investigational first-in-class activin signaling inhibitor in Phase III for pulmonary arterial hypertension, and REBLOZYL (luspatercept) for anemia in rare blood disorders.
Key facts
Announced Sep 30, 2021 Closed Nov 22, 2021 Deal value $11.5B Deal type Acquisition/Merger Therapeutic area Cardiovascular, Hematology, Rare Disease, Respiratory Indications Pulmonary Arterial Hypertension (PAH), Anemia in Myelodysplastic Syndromes, Beta-Thalassemia Key assets sotatercept (PAH), REBLOZYL (luspatercept), TGF-beta superfamily signaling platform Mechanism Activin receptor type IIA-Fc fusion protein (TGF-beta superfamily trap), Erythroid maturation agent
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
The Pharma Closeout — Deal Intelligence Database.
Announcement Sentiment and Outcome Score from sourced facts.Home ·
Deals ·
Methodology ·
About